National Training Standards Approved for AFC in Neuromuscular Medicine
We’re pleased to announce that the Royal College of Physicians and Surgeons of Canada has granted final approval for the National Training Standards for the Area of Focused Competence (AFC) in Neuromuscular Medicine!
This landmark decision marks a major step forward for the neuromuscular community across Canada, paving the way for program accreditation and enhanced clinical training opportunities.
We are also thrilled to share that Dr. Erin O’Ferrall will chair the new AFC committee within the Royal College.
We extend our sincere thanks to all contributors — special thanks to Dr. Hernan Gonorazky and Dr. Erin O’Ferrall — whose dedication and expertise made this milestone possible.
With this approval, PGME offices can now apply for Royal College accreditation to offer AFC training programs. This follows the discipline’s initial recognition in 2022.
Learn More About Clinical Training and Curriculum
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.